Skip to main content

Branko Kopjar

faculty photo
Associate Professor, Health Systems and Population Health


PhD   University of Oslo (Norway), 1996   (Epidemiology)
MS   University of Zagreb (Yugoslavia), 1991   (Biostatistics)
MD   University of Zagreb (Yugoslavia), 1987   (Internal Medicine)

Contact Info


4333 Brooklyn Ave NE, Rm 14-315
Seattle, WA 98195-9455

campus box:   359455
voice:   206-221-3349
fax:   206-543-3964


Dr. Kopjar joined the University of Washington in 1997 after serving as Head of the Section for Preventive Medicine at the Norwegian Institute for Public Health.

During his tenure at UW, he has taught courses in Epidemiology and Critical Evidence Appraisal, Health Program Evaluation and Evidence-based Healthcare Policy. His research interests include: spine and spinal cord injuries and diseases, neurosurgery, orthopaedics, Real World Evidence (RWE) and outcomes research.

As of 2020, he is listed as an author or co-author on over 500 published original articles, reviews, technical reports and abstracts. He serves as a reviewer for various North American and European medical journals.

Dr. Kopjar's work has been recognized with more than 30 honors including the 2005 John M. Eisenberg Article-of-the-Year award, 4 North American Spine Society (NASS) Best Paper awards, and the Outstanding Outcomes Research Award by the American Academy of Neurological Surgeons/Congress of Neurological Surgeons Joint Section on Disorders of the Spine and Peripheral Nerves.

In addition to his role at the University of Washington, Dr. Kopjar serves as a consultant biostatistician to the Food and Drug Administration, Visiting Consultant to the National Health Service Royal Orthopaedic Hospital in Birmingham, U.K., member of the NASS Outcomes Compendium Task Force, member of the NASS Performance Measurement Committee and Lead Investigator, Methods Core, AOSpine North America. He is an elected Fellow of American College of Epidemiology and of the European Academy for Translational Medicine.

From 2014 through 2019, Dr. Kopjar was Director of the University of Washington's Executive Master of Public Health Program.

From 2014-2019, he served as Distinguished Professor, Department of Orthopaedic Surgery, Chongqing Medical University – one of the largest medical institutions in China.

To date, Dr. Kopjar has served as Principal Investigator, Co-Principal Investigator, Study Director or Lead Biostatistician on more than 100 clinical trials across various therapeutic areas including: infectious diseases, orthopaedics, spinal cord injury, bariatric surgery and others. This includes numerous pivotal trials of medical devices in North America and abroad, various Phase 2 and Phase 3 drug studies, and several Post- Market Clinical Follow-up studies. He has participated in federally-funded projects administered through the U.S. Defense Department.

Dr. Kopjar frequently collaborates with industry partners on clinical development efforts. Furthermore, he regularly serves as an expert witness for cases concerning medical device liability and health insurance denial-of-coverage.

In the 2000's, Dr. Kopjar served as adviser to two European health ministers.

Prevention effectiveness; outcomes research; comparative effectiveness; neurosurgery; orthopedics, biostatistics; quality of care; clinical trials
  • HSMGMT 501
    Epidemiology/Critical Evidence Appraisal
  • HSMGMT 501   (EMHA)
    Epidemiology/Critical Evidence Appraisal

Arnold PM, Vaccaro AR, Sasso RC, Goulet B, Fehlings MG, Heary RF, Janssen ME, Kopjar B. Two-Year Clinical and Radiological Outcomes in Patients With Diabetes Undergoing Single-Level Anterior Cervical Discectomy and Fusion. Global Spine J. 2020 Apr 3:2192568220914880. doi: 10.1177/2192568220914880. [Epub ahead of print]  PMID: 32875918    PMCID: PMC8119920
PubMed Central

Davis ET, Remes V, Virolainen P, Gebuhr P, Van Backlé B, Revell MP, Kopjar B. Mid-term outcomes of the R3™ delta ceramic acetabular system in total hip arthroplasty. J Orthop Surg Res. 2021 Jan 9;16(1):35. doi: 10.1186/s13018-020-02192-6.  PMID: 33422084    PMCID: PMC7797157
PubMed Central

Fehlings MG, Badhiwala JH, Ahn H, Farhadi HF, Shaffrey CI, Nassr A, Mummaneni P, Arnold PM, Jacobs WB, Riew KD, Kelly M, Brodke DS, Vaccaro AR, Hilibrand AS, Wilson J, Harrop JS, Yoon ST, Kim KD, Fourney DR, Santaguida C, Massicotte EM, Kopjar B. Safety and efficacy of riluzole in patients undergoing decompressive surgery for degenerative cervical myelopathy (CSM-Protect): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial. Lancet Neurol. 2021 Feb;20(2):98-106. doi: 10.1016/S1474-4422(20)30407-5. Epub 2020 Dec 22.  PMID: 33357512

Davis ET, Pagkalos J, Kopjar B. A higher degree of polyethylene irradiation is associated with a reduced risk of revision for aseptic loosening in total hip arthroplasties using cemented acetabular components: an analysis of 290,770 cases from the National Joint Registry of England, Wales, Northern Island and the Isle of Man. Bone Joint Res. 2020 Sep 20;9(9):563-571. doi: 10.1302/2046-3758.99.BJR-2020-0135.R1. eCollection 2020 Sep.  PMID: 33005395    PMCID: PMC7502255
PubMed Central

Davis ET, Pagkalos J, Kopjar B. Effect of Bearing Surface on Survival of Cementless and Hybrid Total Hip Arthroplasty: Study of Data in the National Joint Registry for England, Wales, Northern Ireland and the Isle of Man. JB JS Open Access. 2020 May 15;5(2):e0075. doi: 10.2106/JBJS.OA.19.00075. eCollection 2020 Apr-Jun.  PMID: 33123668    PMCID: PMC7418917
PubMed Central

Chair, thesis committee for Andre Carvalho
Racial/Ethnic Differences in Head and Neck Cancer Survival Rates

A Multicenter, Randomized Controlled Trial of Cerebrospinal Fluid Drainage in Acute Spinal Cord Injury
St. Joseph's Hospital and Medical Center
PI:   Kopjar           Dates:    6/1/2019 - 9/29/2019

Riluzole in Spinal Cord Injury Study (RISCIS)

The aim of this study is to evaluate efficacy and safety of riluzole in the treatment of patients with acute spinal cord injury (SCI).

Efficacy of Riluzole in Surgical Treatment for Cervical Spondylotic Myelopathy (CSM-Protect)

Study of the efficacy of Riluzole in patients with cervical spondylotic myelopathy undergoing surgical treatment. A randomized, double-blind, placebo-controlled multi-center study